Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity

Research suggests that for patients with rheumatoid arthritis (RA) in sustained low disease activity, tapering biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is as effective as continuing treatment for maintaining disease control over 24 weeks.